Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Amgen, Inc. (NASDAQ:AMGN) by 21.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 116,253 shares of the medical research company’s stock after buying an additional 20,560 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Amgen were worth $21,423,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Advisors Preferred LLC acquired a new stake in shares of Amgen during the 2nd quarter worth approximately $30,000. Arbor Wealth Management LLC boosted its position in Amgen by 154.5% in the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after buying an additional 102 shares during the period. C J Advisory Inc purchased a new stake in shares of Amgen during the 1st quarter worth $40,000. Ashburton Jersey Ltd purchased a new stake in shares of Amgen during the 2nd quarter worth $42,000. Finally, Sound Income Strategies LLC lifted its position in shares of Amgen by 402.1% during the 2nd quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock worth $43,000 after purchasing an additional 189 shares during the last quarter. 78.01% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the transaction, the director now owns 16,336 shares in the company, valued at approximately $2,990,141.44. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the transaction, the director now owns 16,336 shares in the company, valued at approximately $3,064,306.88. The disclosure for this sale can be found here. Insiders sold 4,425 shares of company stock valued at $804,312 over the last quarter. Corporate insiders own 0.25% of the company’s stock.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.58 by $0.39. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. Amgen’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period last year, the firm posted $3.83 EPS. On average, equities research analysts anticipate that Amgen, Inc. will post 14.26 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Thursday, August 15th will be paid a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date is Wednesday, August 14th. Amgen’s dividend payout ratio (DPR) is presently 40.28%.
A number of research analysts have commented on AMGN shares. BidaskClub upgraded shares of Amgen from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Mizuho lowered shares of Amgen from a “buy” rating to a “neutral” rating and upped their target price for the stock from $208.00 to $212.00 in a research report on Monday, August 19th. They noted that the move was a valuation call. BMO Capital Markets upped their price target on shares of Amgen from $230.00 to $240.00 and gave the company an “outperform” rating in a report on Tuesday. Credit Suisse Group reissued an “outperform” rating and set a $225.00 price objective (up previously from $202.00) on shares of Amgen in a research note on Friday, August 16th. Finally, Evercore ISI reaffirmed a “hold” rating on shares of Amgen in a research report on Sunday, August 11th. Ten investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Amgen presently has a consensus rating of “Buy” and an average target price of $215.83.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: How is the S&P 500 index different from the DJIA?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.